Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Tech and Science > Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial : ScienceAlert
Tech and Science

Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial : ScienceAlert

Last updated: June 3, 2025 5:15 am
Share
Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial : ScienceAlert
SHARE

An Exciting Breakthrough in Stomach Cancer Treatment

An innovative new treatment for tackling some of the toughest stomach cancers has shown remarkable promise in a phase 2 clinical trial, leading to significant improvements in tumor shrinkage and survival rates.

The treatment involves a form of CAR T cell immunotherapy, where the body’s own immune cells are extracted, trained to target cancer cells more effectively, and then reintroduced into the bloodstream.

Known as satricabtagene autoleucel, or satri-cel, this therapy targets the CLDN18.2 protein that certain tumors utilize for growth. Patients who received satri-cel in the trial lived approximately 40 percent longer on average.

Researchers from various institutions across China conducted the trial, which involved 156 participants with gastric or gastroesophageal junction cancer that had not responded to at least two previous treatments. These patients were essentially running out of options before participating in the trial.

Survival rate graph
One of the benefits of the treatment was living for longer. (Qi et al., The Lancet,. 2025)

In the satri-cel group, patients had a median average survival of 7.92 months compared to 5.49 months in the control group. Notably, 22 percent of satri-cel patients experienced significant tumor shrinkage, in contrast to just 4 percent of control patients.

The median time before cancer progression was 3.25 months with satri-cel and 1.77 months without, showcasing the treatment’s efficacy across various metrics.

“This brings new hope to patients with otherwise medically untreatable conditions,” remarked oncologist Lin Shen from Beijing Cancer Hospital.

While satri-cel treatment led to significant side effects, including a drop in blood cell counts, researchers believe these side effects are manageable.

CAR T cell therapy has already demonstrated effectiveness in treating blood cancers, and promising results are emerging for solid tumors such as brain cancer and pancreatic cancer. The success seen in treating stomach cancers adds to this growing list of achievements in cancer research.

See also  Is There Thimerosal in Vaccines, And Is It Safe? Here's What The Science Says : ScienceAlert

While this treatment is not a cure, it represents a significant advancement in managing cancer tumors by enhancing the body’s immune response against malignant growths.

“We are further exploring satri-cel’s potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients’ survival, and ultimately pursue potential cures,” Shen added.

The research findings have been published in The Lancet.

TAGGED:cancerclinicalDrugExperimentalhelpedLiveLongerpatientsScienceAlertTrial
Share This Article
Twitter Email Copy Link Print
Previous Article How Life’s Hardest Moments Became My Greatest Teachers How Life’s Hardest Moments Became My Greatest Teachers
Next Article American Eagle Outfitters swings to Q1 loss on higher costs, sluggish demand American Eagle Outfitters swings to Q1 loss on higher costs, sluggish demand
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Yale LISTEN Study participants want to be heard, not politicized

The recent groundbreaking research conducted by the Yale LISTEN Study has shed light on a…

June 10, 2025

RFK Jr. names ACIP members to replace vaccine experts he fired

New Panel of Experts Appointed to CDC Vaccine Policy Committee WASHINGTON — HHS Secretary Robert…

June 11, 2025

Dr. McCullough Reveals the Cancer-Fighting Drug Big Pharma Doesn’t Want You to Know About |

(Note: We appreciate your support for businesses like the one featured in the sponsored message…

May 8, 2025

John F. Kennedy Jr.’s Last Day Alive Revisited 26 Years After Fatal Crash

It has been 26 years since the tragic plane crash that took the lives of…

July 17, 2025

US judge extends Citgo auction’s schedule, moves final hearing to August

A U.S. judge in Delaware has recently announced an extension of the schedule for the…

June 11, 2025

You Might Also Like

Worlds Apart Crossword
Tech and Science

Worlds Apart Crossword

October 10, 2025
Lasers made muon beams, no massive accelerator needed
Tech and Science

Lasers made muon beams, no massive accelerator needed

October 10, 2025
Brain scans reveal where taste and smell become flavor
Tech and Science

Brain scans reveal where taste and smell become flavor

October 10, 2025
Astronomers saw a rogue planet going through a rapid growth spurt
Tech and Science

Astronomers saw a rogue planet going through a rapid growth spurt

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?